CORE--CLINICAL PHARMACOLOGY ANALYTICAL FACILITY
核心--临床药理分析设施
基本信息
- 批准号:6989569
- 负责人:
- 金额:$ 4.52万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-09-22 至 2009-07-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The role of pharmacokinetics (PK) and pharmacodynamics (PD) has increased dramatically as anticancer drug discovery and development has shifted towards molecularly-targeted therapies. Increased appreciation of PKJPD relationships has resulted in increased emphasis on generating and analyzing such data, even for agents without defined molecular targets. Increased recognition of drug-drug interactions and pharmaco-genetic differences in drug metabolism, disposition, and susceptibility has increased the need for assays to define relevant polymorphisms and their clinical impact. The Clinical Pharmacology Analytical Facility (CPAF) was established in 1994 to provide state-of-the-art pharmacology research facilities for the University of Pittsburgh Cancer Institute (UPCI). The CPAF relocated in September 2002 to 1,000 square feet of laboratory space in the Research Pavilion of the Hillman Cancer Center. The CPAF supports preclinical and clinical pharmacology research programs. Services include quantitation of drugs, metabolites, and other materials; identification of metabolites; and PK and PD analyses of anticancer agents that are undergoing clinical trials at UPCI. The CPAF also phenotypes and genotypes cytochrome P450 isoforms and other key drug-metabolizing enzymes. It provides important consultative services to UPCI investigators, on the design of pharmacologic studies and drug assay, metabolism, and PK analyses. The CPAF is directed by Dr. Merrill J. Egorin,
with input from Dr. Robert Bies. The Facility is overseen by an advisory committee, representing the Schools of Medicine and Pharmacy, and the Biostatistics Facility. During the past year, the CPAF has provided support for 29 clinical trials at UPCI, 14 CTEP-sponsored clinical trials at other NCI-designated cancer centers, and 54 animal pharmacology projects. It also provided analytical chemistry support for 3 in vitro, pharmacology studies. To expand its capabilities and increase its value, the CPAF has enhanced substantially its analytical chemistry instrumentation, its PK modeling software, and its personnel. The Facility has acquired two LC/MS instruments and an LC/MS/MS. The CPAF was recognized by Pharsight Corporation as a Center of Pharmaeokinetic Excellence, thereby allowing it to implement sophisticated software. The requested CCSG funding will support Facility personnel for their efforts in providing consultative services related to assay development, methodology, protocol design, and data interpretation, and their efforts in ensuring that instrumentation and software are suitably maintained and available for application to projects by investigators seeking support from the Facility.
随着抗癌药物的发现和开发转向分子靶向治疗,药代动力学(PK)和药效学(PD)的作用显著增加。越来越多的赞赏PKJPD的关系,导致越来越重视产生和分析这样的数据,即使是没有明确的分子靶点的代理。对药物间相互作用和药物代谢、处置和易感性的药物遗传学差异的认识增加,增加了对确定相关多态性及其临床影响的测定的需求。临床药理学分析设施(CPAF)成立于1994年,为匹兹堡大学癌症研究所(UPCI)提供最先进的药理学研究设施。该CPAF于2002年9月搬迁到希尔曼癌症中心研究馆的1,000平方英尺的实验室空间。CPAF支持临床前和临床药理学研究计划。服务包括药物、代谢物和其他材料的定量;代谢物的鉴定;以及正在UPCI进行临床试验的抗癌药物的PK和PD分析。CPAF还对细胞色素P450亚型和其他关键药物代谢酶进行表型和基因型分析。它为UPCI研究者提供重要的咨询服务,包括药理学研究和药物测定、代谢和PK分析的设计。CPAF由梅里尔J. Egorin博士领导,
罗伯特·比斯博士的意见该设施由一个咨询委员会监督,该委员会代表医学院和药学院以及生物统计设施。在过去的一年中,CPAF为UPCI的29项临床试验,其他NCI指定癌症中心的14项CTEP赞助的临床试验以及54个动物药理学项目提供了支持。它还为3项体外药理学研究提供了分析化学支持。为了扩大其能力和增加其价值,CPAF大大增强了其分析化学仪器,PK建模软件和人员。该设施已经获得了两个LC/MS仪器和一个LC/MS/MS。CPAF被Pharsight Corporation认可为药代动力学卓越中心,从而使其能够实施复杂的软件。申请的CCSG资金将支持设施人员提供与检测开发、方法学、方案设计和数据解释相关的咨询服务,以及确保仪器和软件得到适当维护并可用于寻求设施支持的研究人员的项目。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MERRILL J EGORIN其他文献
MERRILL J EGORIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MERRILL J EGORIN', 18)}}的其他基金
Preclinical Pharmacological Studies of Antitumor & Other Therapeutic Agents
抗肿瘤的临床前药理研究
- 批准号:
8177657 - 财政年份:2004
- 资助金额:
$ 4.52万 - 项目类别:
Preclinical Pharmacological Studies of Antitumor & Other Therapeutic Agents
抗肿瘤的临床前药理研究
- 批准号:
7789058 - 财政年份:2004
- 资助金额:
$ 4.52万 - 项目类别:
Preclinical Pharmacological Studies of Antitumor & Other Therapeutic Agents
抗肿瘤的临床前药理研究
- 批准号:
8008916 - 财政年份:2004
- 资助金额:
$ 4.52万 - 项目类别:
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
以 I 期为重点的新型抗癌药物的早期临床试验
- 批准号:
7623201 - 财政年份:2003
- 资助金额:
$ 4.52万 - 项目类别:
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
以 I 期为重点的新型抗癌药物的早期临床试验
- 批准号:
7390997 - 财政年份:2003
- 资助金额:
$ 4.52万 - 项目类别:
Phase I Clinical Trials of Novel Anticancer Agents
新型抗癌药物的I期临床试验
- 批准号:
7209029 - 财政年份:2003
- 资助金额:
$ 4.52万 - 项目类别:
MODELING IN ANTI CANCER DRUG DVMT PRECLINICAL STUDIES THOUGH CLINICAL TRIALS
通过临床试验进行抗癌药物 DVMT 临床前研究建模
- 批准号:
6611245 - 财政年份:2002
- 资助金额:
$ 4.52万 - 项目类别:
MODELING IN ANTI CANCER DRUG DVMT PRECLINICAL STUDIES THOUGH CLINICAL TRIALS
通过临床试验进行抗癌药物 DVMT 临床前研究建模
- 批准号:
6480881 - 财政年份:2001
- 资助金额:
$ 4.52万 - 项目类别:
PRECLINICAL PHARMACOLOGICAL STUDIES OF ANTITUMOR AND ANT
抗肿瘤和ANT的临床前药理学研究
- 批准号:
6352446 - 财政年份:1999
- 资助金额:
$ 4.52万 - 项目类别:
MODELING IN ANTI CANCER DRUG DVMT PRECLINICAL STUDIES THOUGH CLINICAL TRIALS
通过临床试验进行抗癌药物 DVMT 临床前研究建模
- 批准号:
6205821 - 财政年份:1999
- 资助金额:
$ 4.52万 - 项目类别:
相似海外基金
The analysis of proteinuria caused by antineoplastics and the preventative effects with antihypertensive medications using the Japanese medical database
利用日本医学数据库分析抗肿瘤药物引起的蛋白尿及抗高血压药物的预防效果
- 批准号:
21K17258 - 财政年份:2021
- 资助金额:
$ 4.52万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Expediting Drug Development by Profiling Novel Antineoplastics by Mass Spectrometry-based Biomarker Profiling
通过基于质谱的生物标志物分析来分析新型抗肿瘤药物,加速药物开发
- 批准号:
499958-2016 - 财政年份:2016
- 资助金额:
$ 4.52万 - 项目类别:
Engage Grants Program
Uhrf1 and the DNA damage response
Uhrf1 和 DNA 损伤反应
- 批准号:
311915 - 财政年份:2013
- 资助金额:
$ 4.52万 - 项目类别:
Studentship Programs
Improvement of RNAi efficacy by blocking RNAi inhibitors
通过阻断 RNAi 抑制剂提高 RNAi 功效
- 批准号:
7109912 - 财政年份:2006
- 资助金额:
$ 4.52万 - 项目类别:
Development of an ICMT Supported Membrane Sensor
ICMT 支持的薄膜传感器的开发
- 批准号:
7037706 - 财政年份:2006
- 资助金额:
$ 4.52万 - 项目类别:
Develop CEES-induced skin toxicity models and evaluate silibinin efficacy
开发 CEES 诱导的皮肤毒性模型并评估水飞蓟宾功效
- 批准号:
7235521 - 财政年份:2006
- 资助金额:
$ 4.52万 - 项目类别:
PhaseI/II Clinical Trial of hHB22.7 anti-CD22 Monoclonal Antibody for Lymphoma
hHB22.7抗CD22单克隆抗体治疗淋巴瘤I/II期临床试验
- 批准号:
7158852 - 财政年份:2006
- 资助金额:
$ 4.52万 - 项目类别:
Mechanism of Formation of Polysulfane Anticancer Agents
聚硫烷抗癌剂的形成机理
- 批准号:
7059750 - 财政年份:2006
- 资助金额:
$ 4.52万 - 项目类别:
Novel Substrate Competitive Bcr-Abl Inhibitor Active Against Gleevec-Resistant CM
新型底物竞争性 Bcr-Abl 抑制剂对格列卫耐药 CM 具有活性
- 批准号:
7046281 - 财政年份:2006
- 资助金额:
$ 4.52万 - 项目类别: